bnt-211
biontech
['bnt211', 'solid tumor']
patients with relapsed/refractory advanced solid tumors who received the cldn6-direced car t-cell therapy bnt211 with or without the cldn6-encoding mrna vaccine had good efficacy and manageable safety. #asco23 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.